Dashboard
Manage Tickers

INAB IN8BIO, INC.

Nasdaq in8bio.com


$ 1.86 $ -0.04 (-2.11 %)    

Tuesday, 04-Nov-2025 11:44:30 EST
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 622.54 $ -0.71 (-0.11 %)
DIA $ 471.37 $ 1.00 (0.21 %)
SPY $ 677.03 $ 0.90 (0.13 %)
TLT $ 89.93 $ 0.14 (0.16 %)
GLD $ 364.61 $ 1.02 (0.28 %)
$ 1.88
$ 1.90
$ 1.83 x 400
$ 1.87 x 112
$ 1.86 - $ 1.92
$ 1.82 - $ 12.53
68,548
na
8.53M
nm
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-07-2025 06-30-2025 10-Q
2 05-07-2025 03-31-2025 10-Q
3 03-13-2025 12-31-2024 10-K
4 11-12-2024 09-30-2024 10-Q
5 08-08-2024 06-30-2024 10-Q
6 05-09-2024 03-31-2024 10-Q
7 03-14-2024 12-31-2023 10-K
8 11-09-2023 09-30-2023 10-Q
9 08-10-2023 06-30-2023 10-Q
10 05-12-2023 03-31-2023 10-Q
11 03-30-2023 12-31-2022 10-K
12 11-10-2022 09-30-2022 10-Q
13 08-12-2022 06-30-2022 10-Q
14 05-12-2022 03-31-2022 10-Q
15 03-17-2022 12-31-2021 10-K
16 11-10-2021 09-30-2021 10-Q
17 09-10-2021 06-30-2021 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

ohio-state-university-added-as-new-clinical-site-in-ongoing-phase-1-trial-of-in8bios-inb-100-donor-derived-allogeneic-gamma-delta-t-cell-therapy
Ohio State University Added As New Clinica...
10/29/2025 12:05:34

IN8bio, Inc. (NASDAQ:INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies for c...

in8bio-presents-new-preclinical-data-from-gamma-delta-t-cell-engager-program-inb-619-at-2025-acr-convergence-meeting
IN8bio Presents New Preclinical Data From ...
10/27/2025 12:12:25

in8bio-q2-eps-124-beats-170-estimate
IN8bio Q2 EPS $(1.24) Beats $(1.70) Estimate
08/07/2025 20:08:45

IN8bio (NASDAQ:INAB) reported quarterly losses of $(1.24) per share which beat the analyst consensus estimate of $(1.70) by 27....

Core News & Articles
12 Health Care Stocks Moving In Thursday's...
07/10/2025 21:05:48

in8bio-announced-that-a-patient-with-a-grade-4-idh-mutant-glioma-in-a-phase-1-trial-has-been-in-remission-and-surviving-for-4-years-having-been-treated-with-inb-200
IN8Bio Announced That A Patient, With A Gr...
06/09/2025 11:11:30

in8bio-announces-patient-009-in-phase-1-trial-of-inb-200-for-newly-diagnosed-gbm-reaches-significant-clinical-milestone
IN8bio Announces Patient 009 In Phase 1 Tr...
06/09/2025 11:06:50

IN8bio, Inc. (NASDAQ:INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies for c...

us-stocks-likely-to-open-on-a-mixed-note-after-sp-500-scales-6000-mark-whole-globe-is-in-a-bull-market
US Stocks Likely To Open On A Mixed Note A...
06/09/2025 10:21:29

U.S. stock futures were flat on Monday after closing higher on Friday. Futures of major benchmark indices were mixed in premarket.

trading-halt-halt-status-updated-at-85500-am-et-quotation-resumption-news-and-resumption-times
Trading Halt: Halt status updated at 8:55:...
06/06/2025 12:55:12

trading-halt-halted-at-75000-pm-et---trading-halt-halt-news-pending
Trading Halt: Halted at 7:50:00 p.m. ET - ...
06/05/2025 23:50:04

in8bio-to-effect-1-for-30-reverse-stock-split
IN8bio To Effect 1-For-30 Reverse Stock Split
06/04/2025 12:11:29

-SEC Filing

in8bio-announced-new-long-term-clinical-data-from-its-fully-enrolled-phase-1-trial-of-inb-200-in-patients-with-newly-diagnosed-glioblastoma-multiforme-demonstrating-prolonged-progression-free-survival
IN8Bio Announced New Long-term Clinical Da...
06/02/2025 11:32:27

Repeated doses of INB-200 demonstrate extended median progression-free survival (mPFS) of 16.1 months, more than double the exp...

Core News & Articles
12 Health Care Stocks Moving In Thursday's...
05/15/2025 12:09:10

in8bio-presents-preclinical-data-from-inb-619-program
IN8bio Presents Preclinical Data From INB-...
05/14/2025 12:10:09

in8bio-wins-isct-abstract-award-for-analytical-characterization-of-its-gamma-delta-t-cell-therapies-in-inb-100-aml-trial-demonstrating-durable-relapse-free-survival-and-showcasing-consistent-potent-anti-cancer-activity-through-its-proprietary-deltex-allo-manufacturing-platform
IN8bio Wins ISCT Abstract Award For Analyt...
05/12/2025 12:09:30

Company receives ISCT abstract award for the analytical characterization of its manufactured gamma-delta T cell therapies in th...

in8bio-q1-eps-007-inline
IN8bio Q1 EPS $(0.07), Inline
05/07/2025 20:46:06

IN8bio (NASDAQ:INAB) reported quarterly losses of $(0.07) per share which met the analyst consensus estimate. This is a 65 perc...

in8bio-unveils-new-data-from-next-generation-gamma-delta-t-cell-engager-platform-at-aacr-2025
IN8bio Unveils New Data from Next Generati...
04/28/2025 12:11:21

First gamma-delta (γδ) TCE to demonstrate significant γδ T cell expansion and activation, potentially offering an alternative t...

in8bio-to-present-new-preclinical-data-on-novel-gamma-delta-t-cell-engager-platform-for-cancer-immunotherapy-at-aacr-annual-meeting-2025
IN8bio To Present New Preclinical Data On ...
03/31/2025 12:09:51

hc-wainwright--co-maintains-buy-on-in8bio-lowers-price-target-to-6
HC Wainwright & Co. Maintains Buy on IN8bi...
03/14/2025 12:38:28

HC Wainwright & Co. analyst Swayampakula Ramakanth maintains IN8bio (NASDAQ:INAB) with a Buy and lowers the price target...

in8bio-q4-2024-gaap-eps-008-misses-007-estimate
IN8bio Q4 2024 GAAP EPS $(0.08) Misses $(0...
03/13/2025 20:19:42

IN8bio (NASDAQ:INAB) reported quarterly losses of $(0.08) per share which missed the analyst consensus estimate of $(0.07) by 1...

in8bio-presented-phase-1-data-on--inb-100-at-2025-transplantation--cellular-therapy-meetings-in-hawaii-says-latest-findings-demonstrated-long-term-remissions-with-no-aml-patient-relapses-observed-to-date-with-median-follow-up-of-201-months
IN8bio Presented Phase 1 Data On INB-100 ...
02/14/2025 14:05:31

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION